Sintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Darolutamide is a non-steroidal androgen receptor inhibitor used in oncology. Its core synthesis involves complex organic coupling reactions. The chemical formula is <strong>C<sub>24</sub>H<sub>28</sub>N<sub>6</sub>O</strong> with CAS number <strong>1059729-33-7</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing:</strong> Active Pharmaceutical Ingredient (API) production for metastatic castration-resistant prostate cancer.</li>
<li><strong>Clinical Research:</strong> Key component in combination therapies with ADT for disease progression management.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated during pregnancy due to fetal harm risks. Requires storage below 25°C in dry, light-protected environments. Personnel must utilize appropriate PPE to prevent dermal exposure during handling.</p>